209 related articles for article (PubMed ID: 35938988)
1. IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2.
Hale M; Netland J; Chen Y; Thouvenel CD; Smith KN; Rich LM; Vanderwall ER; Miranda MC; Eggenberger J; Hao L; Watson MJ; Mundorff CC; Rodda LB; King NP; Guttman M; Gale M; Abraham J; Debley JS; Pepper M; Rawlings DJ
J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35938988
[TBL] [Abstract][Full Text] [Related]
2. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
[TBL] [Abstract][Full Text] [Related]
5. Isotyping and quantitation of the humoral immune response to SARS-CoV-2.
Goyins KA; Yu JJ; Papp SB; Beddard R; Murthy AK; Chambers JP; Arulanandam BP
Exp Biol Med (Maywood); 2022 Jun; 247(12):1055-1060. PubMed ID: 35369776
[TBL] [Abstract][Full Text] [Related]
6. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
7. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
Gasser R; Cloutier M; Prévost J; Fink C; Ducas É; Ding S; Dussault N; Landry P; Tremblay T; Laforce-Lavoie A; Lewin A; Beaudoin-Bussières G; Laumaea A; Medjahed H; Larochelle C; Richard J; Dekaban GA; Dikeakos JD; Bazin R; Finzi A
Cell Rep; 2021 Mar; 34(9):108790. PubMed ID: 33596407
[TBL] [Abstract][Full Text] [Related]
8. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR; Ku Z; An Z; Carroll SF; Keyt BA; Strohl LM
BioDrugs; 2022 May; 36(3):231-323. PubMed ID: 35476216
[TBL] [Abstract][Full Text] [Related]
9. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R
Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
Yue S; Li Z; Lin Y; Yang Y; Yuan M; Pan Z; Hu L; Gao L; Zhou J; Tang J; Wang Y; Tian Q; Hao Y; Wang J; Huang Q; Xu L; Zhu B; Liu P; Deng K; Wang L; Ye L; Chen X
Front Immunol; 2021; 12():751584. PubMed ID: 34630430
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
13. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
14. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
Pang NY; Pang AS; Chow VT; Wang DY
Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
Demers-Mathieu V; DaPra C; Medo E
Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
[No Abstract] [Full Text] [Related]
16. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
[TBL] [Abstract][Full Text] [Related]
17. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
18. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
19. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
20. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C; Fernández I; Bruel T; de Melo GD; Prot M; Beretta M; Guardado-Calvo P; Dufloo J; Molinos-Albert LM; Backovic M; Chiaravalli J; Giraud E; Vesin B; Conquet L; Grzelak L; Planas D; Staropoli I; Guivel-Benhassine F; Hieu T; Boullé M; Cervantes-Gonzalez M; Ungeheuer MN; Charneau P; van der Werf S; Agou F; ; ; Dimitrov JD; Simon-Lorière E; Bourhy H; Montagutelli X; Rey FA; Schwartz O; Mouquet H
J Exp Med; 2022 Jul; 219(7):. PubMed ID: 35704748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
